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Globally, nineteen million children under 15 years are estimated to be visually impaired. The 
socioeconomic impact of sight threatening illnesses cannot be ignored, since those most 
affected live in low income countries, where employment opportunities are few and up to 90% 
who reach adulthood, are unemployed (1). 
In 2011, sight disabilities constituted 32% of all disabilities reported in South Africa, of which 
children older than 5 years comprised 11%. Refractive errors were the most common cause 
cited but apart from retinopathy of prematurity, the outcome of disease processes (cataracts, 
raised intra-ocular pressure and corneal scarring) was described (2). 
Understanding the underlying causes of visual impairment is essential for prevention, treatment 
and the improvement of overall visual outcomes. 
Uveitis is an important cause of blindness, with children comprising 5–10% of most tertiary 
uveitis clinic populations (3). Involving inflammation of the iris, choroid and retina, sight 
threatening complications may result from unrecognized persistent disease activity or the side 
effects of ongoing treatment. This is particularly devastating in children and may result in 
severe vision loss in up to 50% of cases (4, 5). 
 
 
Uveitis aetiology may be classified as either infectious, post infectious or non-infectious, while 
masquerade syndromes are essential considerations in the differential diagnosis. 
The commonly described infectious entities in predominantly adult studies from the developing 
world include herpes, toxoplasmosis, tuberculosis (TB), cytomegalovirus (CMV) and its 
association with human immunodeficiency virus (HIV), syphilis and parasites. These comprise 
around 30% - 50% of all cases described and may present as an acute, painful red eye and with 
visual disturbance (6). 
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There is a paucity of literature describing uveitis in children from South Africa, though 
historically, a study from 1974 showed unknown, idiopathic anterior uveitis to be more 
common in Black children (7). More recently, HIV as a cause of uveitis, in a case series of 7 
children with HIV associated arthritis (8) and streptococcal infection presenting as a post- 
infectious immune mediated syndrome (9), has been described. Reviews in the adult 
population, showed infectious aetiology to account for almost 50% of cases compared to 18.2% 
for non-infectious uveitis (10,11). To date, there are no recent studies reviewing non-infectious 
uveitis per se, in children from Sub-Saharan Africa. 
In developed countries, however, infectious causes contribute significantly less (between 11- 
20%) to the total uveitis burden, with TB and syphilis accounting for less than 3% (6). Here, 
non-infectious uveitis is more common and is associated with specific immune mediated 
disease including juvenile idiopathic arthritis (JIA), HLA-B27 associated diseases, sarcoidosis 
and Behcet’s among others. Additionally, idiopathic uveitis is considered an almost equal 
contributor in children. Less is known about the associated risk factors for idiopathic uveitis, a 
diagnosis based on exclusion, but preceding undetected infection may be a trigger (3). 
 
 
In childhood, JIA an umbrella term for a heterogenous group of disorders, is considered the 
most common immune mediated disease, with a prevalence rate of 1-4:1000. Uveitis is a well 
described extra articular manifestation (12) and is the main focus of this review. 
The pathogenesis of juvenile idiopathic arthritis associated uveitis (JIA-U) has remained 
elusive, though a shared antigen with synovial tissue is postulated. Research is predominantly 
in animal models, mostly due to the lack of adequate human iridectomy and aqueous humour 
specimens. Anti-nuclear antibody (ANA) positivity appears to be the most consistent feature 
and while disease activity is attributed to an imbalance between t-regulatory and t-effector 
cells, research into clarification of the disease pathway is ongoing (13). 
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The use of the International League of Associations for Rheumatology (ILAR) classification 
of JIA in conjunction with the Standard Uveitis Nomenclature (SUN) criteria proposed in 2005, 
has allowed comparisons of presentation, visual complications and outcomes between studies 
(14, 15). 
Current literature describes JIA-U as occurring in about 20% of children with JIA, 
predominantly in girls of European descent, who present with the oligo-subtype and are ANA 
positive. JIA-U also occurs in the poly-articular JIA rheumatoid factor (RF) negative subtype. 
In these subtypes, children often present late, with an asymptomatic chronic insidious onset 
and more severe, complicated disease than their adult counterparts. An acute anterior uveitis 
may also be seen in psoriatic JIA and the HLA-B27 associated enthesitis related arthritis (ERA) 
subtype (16,17). 
Children may present with uveitis as the first sign of JIA with no evidence of arthritis at initial 
diagnosis. JIA may subsequently develop, an indication that ongoing joint assessment is 
necessary. Alternatively, children could present with JIA and uveitis found incidentally on 
screening. A mean time to onset of JIA-U of 1.8 years has been described despite concurrent 
treatment for JIA and a second peak of uveitis activity is also thought to occur around puberty, 
which necessitates ongoing screening (18). 
While the oligo-articular arthritis association with JIA-U is well described, female 
preponderance and ANA positivity have been questioned (19). Young age also appears to be a 
risk factor for the development of uveitis in girls but less so in boys. The role of ethnicity on 
poor visual outcome is uncertain, though it is still suggested that girls of European descent are 
at higher risk. Additional risk factors for vision loss include the presence of uveitis before 
arthritis, young age at onset, complications at presentation, short duration between arthritis 
onset and uveitis, multiple episodes and male sex (14, 20). 
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Screening algorithms based on the SUN criteria have been developed for JIA-U, taking this 
into account (21). 
Treatment strategies for uveitis have changed since the 1990’s. Recent consensus treatment 
guidelines for JIA-U and idiopathic uveitis in children, advocate the use of biologic therapies 
to mitigate the side effects of steroids. To achieve optimal control as quickly as possible and 
improve long-term visual outcomes, these guidelines suggest the use of specific tumour 
necrosis factor inhibitor treatment, following failure of methotrexate to achieve disease 
remission within 3 months (21-23). 
Despite this, children with JIA-U have shown significant ocular morbidity and up to 50% have 
visual impairment or blindness of at least one eye and require surgery during the course of the 
disease. This may be due to active uveitis but also occur as a side effect of treatment. Follow 
up studies of children with JIA-U have shown persistent activity into adulthood requiring 
ongoing assessment and treatment (24, 25). The few studies from low and middle income 
countries tend to support the view that children with JIA have increased morbidity and 
complications (26). Uncertainty remains regarding the duration of treatment but a minimum of 
2 years of remission is advocated before withdrawal is considered (27, 28). 
Uveitis associated with other immune mediated diseases are far less common. Behcet’s disease 
is more often seen along the former silk route with a low paediatric prevalence estimated 
between 0.03 and 0.2 per 1000. Uveitis is listed as one of six criteria for diagnosing Behcet’s 
(though retinal vasculitis is more common) and may be the first presentation in up to 10% of 
cases, predominantly in boys over 10 years old and can occur up to two years after the initial 
diagnosis (29-31). Studies from North Africa and the Middle East therefore show a slightly 
different immune mediated uveitis spectrum to their western counterparts. Behcet’s is more 
commonly described, JIA and sarcoidosis less so (32,33) while idiopathic uveitis comprised 
up to 50% of studies from elsewhere in Africa (32,34). 
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While 1 – 3% of paediatric uveitis referrals are due to sarcoidosis, the specific prevalence is 
not known. Sarcoidosis may affect any part of the eye and the granulomatous uveitis may 
present with acute anterior chamber inflammation or with posterior chamber involvement. 
Early age of onset is associated with the familial Blau syndrome, characterised by a triad of 
uveitis, dermatitis and arthritis (35). 
SLE associated uveitis is considered very uncommon with the prevalence estimated at around 
 
0.47 per 1000 in adults. It is rarely reported in children but uveitis may in addition, occur as 
a result of medication rather than the disease process itself (36). 
 
 
Other immune mediated uveitis associated with anti-neutrophil cytoplasmic antibody mediated 
vasculitides and Kawasaki’s disease are also rare. Recent reports have considered anterior 
uveitis as an aid in the diagnosis of incomplete Kawasaki’s disease (37,38) although uveitis is 
not part of the current diagnostic criteria. 
These comorbidities impact further on overall treatment and long-term outcome. 
 
 
Non-infectious immune mediated uveitis, particularly when associated with JIA, may thus be 




To our knowledge, this will be the first description of children with non-infectious uveitis, co- 
managed at a paediatric rheumatology service from Sub-Saharan Africa. 
This study may be useful in defining associated co-morbidities, reassessing currently available 




To describe the presentation, associated disease characteristics and treatment outcomes of 
children with non-infectious uveitis, co-managed at a tertiary paediatric rheumatology (PR) 
service in Cape Town 
Objectives 
1. To describe the overall spectrum of children co-managed with non-infectious uveitis at
the PR service in Cape Town
2. To describe the presentation, disease characteristics and treatment outcomes of children
with non-infectious uveitis
Methods 
Study Setting and Population 
The paediatric rheumatology and ophthalmology tertiary referral service in Cape Town are 
based at Groote Schuur and Red Cross Children’s Hospitals. These hospitals are the main 
referral units for the Western Cape as well as other provinces in South Africa, where paediatric 
rheumatology services may be minimal or absent. Referred children are from a broad ethnic 
spectrum and varying socioeconomic circumstances. 
Sample Size 
An estimated sample size of 150-200 children diagnosed with JIA is expected, based on PR 
clinic attendance statistics 
JIA-U prevalence is estimated at 10 -20% in reported literature. An estimated sample size of 
15-40 children is anticipated.
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Data Collection (Appendix A) 
Inclusion criteria 
1. Data will be extracted from case files of all patients reviewed at the paediatric
rheumatology and ophthalmology service for non-infectious uveitis and JIA from 1
January 2010 to 31 December 2017.
2. Children with uveitis will be identified from a systematic review of paediatric
rheumatology (PR) case files, correlated with clinic attendance books, ophthalmology
clinic attendance records and confirmed on Clinicom.
3. Similarly, children with JIA will be identified from PR clinic attendance books and
confirmed on Clinicom.
This will minimise missed records and allow maximum relevant data collection. 
4. Data of patients identified with non-infectious uveitis will include age, gender, date of
diagnosis, time to diagnosis as well as:
o Clinical presentation: visual acuity and complications
o Disease characteristics: associated diseases, antibody profile, anatomical
location of uveitis
o Treatment modalities utilized
o Treatment outcome defined according to SUN (15) criteria
o Remission defined as  3months of inactive disease on treatment
5. Data of patients with JIA will additionally include JIA subtype, time to uveitis diagnosis
and whether JIA remission was achieved.
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6. Primary Outcome considered as inactive disease on treatment 
 







All children assessed at the PR service prior to 1 January 2010 to 31 December 2017, with 
infectious chronic uveitis will be excluded. 
Those treated for less than 3 months or were lost to follow up during the study period, will be 





Children referred to the PR service have a high likelihood of an immune mediated disorder, 





This is a retrospective case file review and will depend on the availability and accuracy of the 
medical records included in the study. 
Patient records may be missed if clinic appointments were not booked or recorded. 
 




Statistical analysis will be done utilizing STATA13. 
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Descriptive statistics will be employed for categorical variables to determine measures of 
central tendency e.g mean, median, mode. Chi- squared or F i s he r  exac t  testing and t- tests 
for comparisons between groups, will be used as appropriate to evaluate associations with 
p<0.05 considered significant. 
 
Privacy and confidentiality 
Data protection and storage 
Approval for data collection from Red Cross Children’s Hospital and Groote Schuur Hospital 
was sought . 
Data will be anonymised and collected in accordance with the principles of Helsinki and Good 
Clinical Practice. 
Data will be transcribed onto a password protected electronic data sheet with identifying data 
removed. Data will then be stored in a password protected database to which only the PI and 
sub-investigator will have access. 
 
 
On completion, the data will be made available for further study as part of the paediatric 
rheumatology database and repository. 
 
 
The completed study will be submitted to the School of Paediatrics and Child Health, 
University of Cape Town in partial fulfilment of the MPhil Paediatric Rheumatology (sub- 
speciality training) and be made available for publication. 
 
 
There are no conflicts of interest 
This is a non-funded study. 
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Uveitis is an important cause of blindness worldwide and may be classified by anatomical 
location, histopathology or by aetiology as infectious, post infectious or non-infectious. These 
terms encompass a range of underlying diseases, the clinical presentation depending on which 
areas of the uveal tract and adjacent structures are most affected. 
 
 
Non-infectious uveitis is associated with systemic immune mediated disorders including 
juvenile idiopathic arthritis (JIA), human leukocyte antigen (HLA) B27 associated diseases, 
sarcoidosis and Behcet’s disease (BD) in children. Idiopathic uveitis, an isolated ocular 
presentation with no evidence of systemic disease is often reported, as well as Fuch’s 
heterochromic iridocyclitis (FHI), Vogt-Koyonagi-Harada syndrome (VKH) and 
tubulointerstitial nephritis with associated uveitis (TINU) (1-3). 
 
 
Additionally, the acknowledged management difficulties in frequently asymptomatic children 
and the resultant long-term morbidity and complications, underscores the need for expertise in 





Here, we aim to review the epidemiology, characteristics and treatment of diseases associated 
with non-infectious uveitis in African children. 
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Literature search strategy 
 
• A literature search was performed in the MEDLINE (PUBMED), Scopus and Cochrane 
library databases (Appendix C) 
• Search terms included: Non-infectious uveitis child Africa, epidemiology non- 
infectious uveitis child, non- infectious uveitis child treatment Africa, juvenile 
idiopathic arthritis Africa, paediatric SLE Africa 
• Inclusions 
o Only articles in English with titles and abstracts deemed appropriate published 
up to October 2019 were considered 




o Duplicate studies due to overlapping search terms 
 
o Literature only relating to infectious uveitis 
o Literature where the paediatric subset was not well defined in combined adult- 
paediatric studies 











In tertiary referral centres in developed countries, the ocular manifestations of non-infectious 
immune mediated diseases are well-described and infectious causes do not contribute 
significantly to the total uveitis burden (2). Gender may influence the type of inflammation, 
where a male preponderance in HLA B27 associated acute anterior uveitis is seen, although 
the influence of race and ethnicity needs further elucidation (5-7). 
This is in contrast to Africa and other developing countries, where infectious diseases cause up 
to 60% of uveitis and depending on geographic location, may be due to parasites, leptospirosis, 
tuberculosis and herpes virus among others. Syphilis, toxoplasmosis, onchocerciasis, 
cytomegalovirus and its association with human immunodeficiency virus (HIV) are considered 
in posterior uveitis, as well as human T-cell leukaemia virus type-1 in intermediate uveitis. 
Panuveitis is also frequently described. Here a male preponderance is often reported and 
ascribed to health seeking behaviour and access. Non-infectious causes are less frequently 






A detailed review of the immune mediated diseases associated with non-infectious uveitis has 
been reported previously (9-11). Here the main focus is on JIA and the immune mediated 
diseases associated with uveitis described in African children. 
 
 
Juvenile Idiopathic Arthritis 
 
JIA, a heterogenous group of disorders currently classified according to the International 
League of Associations for Rheumatology (ILAR) criteria, is the most common immune 
mediated disease in children, with a prevalence of 1-4:1000 (12). Although JIA associated 
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uveitis (JIAU) is well researched in developed countries (13-15), the pathogenesis has 
remained elusive. A shared antigen with synovial tissue is postulated and disease activity 
attributed to an imbalance between t-regulatory and t-effector cells. Antibody production, as 
evidenced by ANA positivity, appears to be the most consistent feature (16,17). 
Current developed country literature describes up to 20% of JIAU as an asymptomatic chronic 
insidious anterior uveitis, occurring more frequently in oligo-articular and poly-articular 
rheumatoid factor (RF) negative children. An acute anterior uveitis may be seen in psoriatic 
JIA and the HLA-B27 associated enthesitis related arthritis (ERA) subtype (18). 
 
 
JIA and JIAU data from Africa are summarised in Table 1. 
 
Difficulties in comparison occurred when data was not defined according to the ILAR criteria 
(12). However, varying frequencies of JIA subtypes, notably 7-52% oligo-articular and 7-21% 
RF negative poly-articular JIA, which may influence the frequencies of JIAU, are apparent. 
Three studies from North Africa report JIAU frequencies of 6.25% (not included in Table 1 as 
JIA data is not further detailed) to 19.7%, with ANA positivity of up to 50% in two. Seven JIA 
studies from SSA indicate JIAU frequencies of 1.5 – 12.8% but of three South African studies, 
only two from Kwazulu Natal reported JIAU. Also, only two studies provided details of the 
anatomical location of uveitis where most were chronic anterior and were correlated with ANA 
positivity and JIA subtype. Different to developed country studies, sub-Saharan African (SSA) 
children were predominantly male, were invariably ANA negative or not tested and did not 
have oligo-articular but polyarticular JIA. RF and HLAB27 were minimally reported, however 
the availability and cost of diagnostic testing is specifically mentioned by the respective authors 
as reasons for waiving testing (19-27, 32). 
Table 1: Summary of JIA and JIAU data from Africa 




































Single Single Two Single Single single Single Single 
Total N 60 97 23 78 85 68 28 30 132 
JIA subtypes (%) 
Oligo 36.7 39 7 26 32.1 23.5 39.3 30 52.2 
Poly RF- 26.6 30 
13 
14 34.6 38.2 42.8 
16.7 
21.2 
Poly RF+ 21.6 9 26.9 11.5 17.6 7.1 8.3 
ERA 0 5 0 23 6.4 5.9 0 26.7 4.5 
Psoriatic 0 0 0 1.3 1.3 0 0 0 0 
SJIA 15 16 3 7.7 14.1 14.7 17.9 23.3 13.6 
Undifferentiated 0 0 0 0 0 0 0 0 0 
Uveitis (%) 8.3 4 8.7 0 12.8 1.5 7.1 13.3 19.7 
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HLA B27 associated diseases 
HLA B27 associated uveitis is the second most common cause of uveitis in the developed world. The 
acute anterior uveitis is most frequently seen in young males with ankylosing spondylitis (28). 
However, the frequency of HLA B27 is reported as <1% in SSA and despite higher frequencies in 
West African populations, ankylosing spondylitis is rarely seen (29, 30). Khairallah et al reported 2.8% 
HLAB27 associated uveitis and one child with uveitis and Crohn’s Disease from North Africa in 
another study, where HLAB27 was not reported (31, 32). Importantly, an increasing number of HLA 
B27 negative spondyloarthropathies have been seen in association with HIV from Africa. Data in SSA 
children is limited to two case series of children with HIV associated polyarthritis and uveitis (20, 33). 
Behcet’s Disease 
BD disease has a high association with HLAB51, is more often seen around the Mediterranean basin, 
Middle and Far East and has a low paediatric prevalence estimated between 0.03 and 0.2 per 1000. 
Uveitis may be the first presentation in up to 10% of cases, predominantly in boys over 10 years old 
or may occur up to two years after the initial diagnosis (5, 34). Few adult studies from Africa and 
paediatric uveitis studies from North Africa, show worse disease activity and poorer outcomes (32,35- 
38). There are however, no reports of BD in children from SSA. 
Sarcoidosis 
While 1 – 3% of paediatric uveitis referrals are due to sarcoidosis, the specific prevalence is not known. 
Early age of onset is associated with the familial Blau syndrome and late onset with more systemic 
systems (39,40). Studies in adults have reported an increased risk based on ethnicity (41) however, 
there are no similar studies in children. A French cohort involving mostly African American and SSA 
immigrant children with pulmonary sarcoidosis, reported 17.1% as having ocular manifestations but 
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this was not further elucidated (42). There are no African studies of sarcoidosis nor associated uveitis 
in children, as far as we were able to ascertain. 
Systemic Lupus Erythematosus (SLE) 
SLE associated uveitis is very uncommon and is rarely reported in children. A large retrospective 
cohort study from Brazil showed 0.8% of children with uveitis, notably with higher SLE disease 
activity scores. However, no uveitis was reported in two significant paediatric case series from South 
Africa and one from Nigeria (43-46, 86). 
Vogt Koyanagi Harada (VKH) 
VKH syndrome, is a rare T-helper cell 1 lymphocyte mediated anti-melanocyte disease affecting 
Asian, Middle Eastern, Hispanic and Native Americans and is rarely reported from Africa. The global 
incidence of VKH varies from 1-7% and usually presents in the second to fifth decades, although 
children may also be affected. Only one child with VKH has been reported in a North African study 
(31). 
Post streptococcal syndrome 
Post infectious streptococcal immune mediated uveitis has historically been described by Cokingtin 
and Han and a large case series from South Africa once again highlighted the importance of this 
disease. A case series from Northern Ireland reported the successful use of tumour necrosis factor 
inhibitor treatment for refractory cases but similar data from Africa has not been published (47- 49). 
Other 
Uveitis presenting in TINU (associated with common infections and medication) and FHI (recently 
associated with the rubella virus), comprise 2-7% of uveitis clinic referrals in North America. Uveitis 
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in anti-neutrophilic cytoplasmic antibody associated vasculitides, Kawasaki’s disease and auto- 
inflammatory syndromes are rarely described (50-55). 
No paediatric cases have been reported in African literature. 
In summary, some data for immune mediated diseases, particularly JIA in SSA children, has emerged 
from Africa in recent years with limited focus on the ocular manifestations and its treatment. 
Treatment 
Uveitis management involves treatment of the underlying disease, the ocular inflammation and the 
complications. Initial treatment of anterior uveitis typically includes topical corticosteroids and 
cycloplegics. Systemic corticosteroids are initiated when topical therapy fails or in the context of 
severe ocular or systemic disease. 
JIAU and idiopathic uveitis 
Recent consensus treatment guidelines for chronic anterior uveitis in JIA-U and idiopathic uveitis, 
advocate a step-up approach if control is not achieved within 3 months of initiating a new therapy. 
Limited evidence for the efficacy of methotrexate, other DMARD’s and biologics, support their use to 
mitigate the side effects of steroids (56-62). 
Intra-ocular and intravitreal corticosteroid injections are utilised in the management of intermediate 
and posterior uveitis. However, while evidence from two small case series on intravitreal 
dexamethasone implants showed improvement of visual acuity, raised intraocular pressure and relapse 
in 36.4% of children were noted (63-65). 
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Ongoing research for additional biologics used in cases refractory to TNFi, are summarised in 
Appendix D (66-81, 87). 
As yet, uncertainty remains regarding the duration of treatment but a minimum of 2 years of inactive 
disease is advocated before withdrawal is considered. In addition, children often require surgery during 
the course of their disease (25,82,83). 
Other diseases 
Treatment options for other diseases include early systemic corticosteroids and DMARDs in BD and 
VKH, as well as tumour necrosis factor and interleukin 1 inhibitors in refractory sarcoid uveitis. 
In children with FHI, a poor response to topical steroids with the development of raised intraocular 
pressure may occur and surgery required earlier in the disease course (40,52,84,85). 
These treatment options are predominantly based on developed countries data and expert opinion. 
There are no studies or clinical trials from Africa for the management of non-infectious uveitis. 
Limitations 
The review is limited by: 
• One reviewer’s selection bias as to relevance
• Exclusion of articles in languages other than English, as French in particular is the official
language of at least 21 countries in Africa
Gaps in literature 
Non-infectious uveitis is well reported in developed countries with scant data available from Africa. 
Literature from North Africa shows a different disease spectrum to developed countries and 
importantly, the data for post infectious immune mediated syndromes and the uveitis related to 
31 
HLAB27 negative spondyloarthropathies associated with HIV infection, suggests the need for further 
investigation. Despite more publications on immune mediated diseases in children from SSA becoming 
available, the data for their ocular manifestations are limited and relatively poorly defined. 
Conclusion 
Further study of the presentation and treatment of non-infectious uveitis in African children is needed 
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Data collection and storage 
 
No human or animal subjects were involved, as a retrospective case file review was performed. 
Specific consent/assent was therefore not required from patients. 
Data was anonymised and collected in accordance  with  the  principles  of  Helsinki  and  GCP.  Data 
was transcribed onto a password-protected electronic data sheet with identifying data removed. Data 
is stored in a password-protected database to which only the PI and sub-investigator has access. 
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Uveitis is a known cause of blindness in the developed world, where non-infectious diseases dominate 
the spectrum of underlying aetiologies. However, data from sub-Saharan Africa is lacking. Here we 
aim to describe the diseases associated with non-infectious uveitis and the impact of currently available 
treatment in this setting. 
Methods 
 
A retrospective observational analysis of children with non-infectious uveitis from January 2010      to 
December 2017, attending the tertiary paediatric rheumatology and  ophthalmology  referral units in 
Cape Town was conducted. Statistical analysis  utilising  STATA13  software  was performed with p 
< 0.05 considered significant. 
Results 
 
Twenty-nine children were identified with a median age at first visit of 74 months (IQR 49–86 months), 
female to male ratio of 0.9:1, predominantly of mixed race (72.4%). 
Juvenile idiopathic arthritis associated uveitis (JIAU) (48.3%) was the most frequent diagnosis. All 
children with JIAU had chronic anterior uveitis and 3 (21.4%) presented with uveitis before arthritis. 
There were no differences between children with uveitis and those with arthritis  only, for gender    (p 
= 0.68) and race (p = 0.58) but significantly, children with uveitis presented at an overall younger age 
(p = 0.008), with antinuclear antibody positive (p < 0.001) oligo-articular JIA (p = 0.01) and older age 
appeared to be protective (p = 0.01 OR1.0 CI 0.6-1.7). 
Children with idiopathic uveitis (41.4%) were predominantly male (66.6%), of mixed race (75%), with 
chronic anterior uveitis (41.7%) and presented with cataracts (100%). 
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Less commonly, sarcoidosis (6.9%) and Behcet’s disease (3.5%) were diagnosed. 
55.2% had complications at presentation, predominantly cataracts (87.5%). 19 children (65.5%) had 
inactive disease at 12 months from diagnosis and remission, as assessed at the last clinical visit was 
achieved in 58.6% on standard initial therapy and in 75% of those on tumour necrosis factor 
inhibitors. Surgery was needed in 41.4%, primarily in the idiopathic group. Visual acuity improved 





The spectrum and characteristics of immune mediated non-infectious uveitis are comparable to that 
reported in developed countries. Current practice detects children with potentially sight-threatening 








Uveitis broadly describes inflammation of the iris, choroid and retina, occurring when the blood- 
aqueous and blood-retinal barrier is disrupted by infectious or non-infectious triggers. An important 
cause of 16–25% of blindness worldwide, the estimated paediatric prevalence of 28:100 000, is at least 
4 times lower than in adults (1). However, the sight-threatening consequences due to late presentation 
and aggressive disease are far reaching in children, particularly in developing countries where 
employment opportunities for the visually impaired are limited (2). 
Epidemiology studies highlight the paucity of data from Africa and other developing countries, noting 
potential differences in the prevalence and demographics of underlying aetiologies as well as in 
outcomes (1,3). Sub-Saharan Africa (SSA) data tend to under report uveitis in the context of surveys 
or studies on blindness in a specific region (4-7). Only active uveitis resulting in visual loss is 
documented and outcomes including cataracts and glaucoma are recorded, as in South African statistics 
(8). Additionally, studies predominantly describe adult populations and infectious diseases, where 30 
– 50% are caused by herpes, toxoplasmosis, tuberculosis, cytomegalovirus and its association with 
human immunodeficiency virus (HIV), syphilis and parasites (9-12). Post streptococcal syndrome and 
HIV associated uveitis have recently been described in children (13-15). Idiopathic uveitis, where an 
underlying systemic cause cannot be found, frequently presents with complications and still accounts 
for up to 50% of uveitis populations seen at referral centres (16). The utility of microbial polymerase 
chain reaction and culture as well as cytospin of fluid obtained by ocular paracentesis, has been 
established in determining a cause for up to one third of previously reported cases of idiopathic uveitis 
(17,18).  However, the technical aspects of the procedure in children and analysis of the small amounts 
of fluid obtained, remains a challenge in many under resourced countries.  
The limited data for immune mediated uveitis in SSA children describe the association with juvenile 
idiopathic arthritis (JIA) (19-22).  Reports from North Africa, additionally describe uveitis in Behcet’s 
disease (BD) (23-25). However, uveitis presenting in other immune mediated diseases are not featured. 
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In developed countries, non-infectious uveitis is a more recognized ocular manifestation of systemic 
immune mediated diseases and in children, is frequently described in JIA, HLA-B27 associated 
diseases, sarcoidosis and BD among others. Here, infectious diseases contribute significantly less to 
the total uveitis burden, with TB and syphilis accounting for under 3% (1,3). 
The prevalence of paediatric immune mediated systemic diseases and the associated uveitis, varies by 
underlying disease, disease subtype, as well as geographically (26). Notably BD is reported more 
frequently from countries around the Mediterranean basin and the Far East (1). In JIA, where the 
highest prevalence is seen in European and western countries, up to 20% of chronic anterior uveitis 
occurs in the oligo-articular subtype in young girls under 7 years old of Caucasian race, who are ANA 
positive. Associations with race as a predictor of more aggressive disease and poorer outcomes has 
been described, although research in this area is ongoing. Acute anterior uveitis may also be seen in 
enthesitis-related arthritis and psoriatic JIA, as well as in other HLA B27 associated diseases (27-31). 
The potential risk of amblyopia and poor long-term outcomes secondary to persistent disease activity 
and prolonged corticosteroid treatment in children is recognized. The standard uveitis nomenclature 
(SUN) working group classification and screening guidelines, though not formally validated in 
children, has improved cross-study comparisons. This has aided monitoring of treatment responses and 
decisions to escalate therapy (32,33). Management by experienced ophthalmologists and 
rheumatologists is thus advocated, as refractory disease often requires the addition of disease 
modifying anti-rheumatic drugs (DMARDs) and biologics. The recent Single Hub and Access point 
for paediatric Rheumatology in Europe (SHARE), Childhood Arthritis and Rheumatology Research 
Alliance (CARRA) and American College of Rheumatology (ACR) consensus guidelines, for chronic 
anterior uveitis in JIA and idiopathic uveitis, are based on expert opinion and evidence from developed 
countries (34-37). These consider DMARDs including azathioprine, mycophenolate mofetil and 
cyclosporine rescue therapy in conjunction with methotrexate, within 3 months of failure to achieve 
optimal control of inflammation with corticosteroids. Tumour necrosis factor inhibitors (TNFi) have 
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proven efficacy in recent clinical trials (38,39) and are also advocated in these treatment algorithms. 
Smaller case series for other biologics, including rituximab, tocilizumab a n d  abatacept have 
yielded promising results in cases refractory to TNFi (40-45). No data for the use of biologics for non- 
infectious uveitis in SSA children has been published, although in South Africa, biologic treatment in 
the last 10 years despite limitations of cost and availability, is noted anecdotally. 
Understanding the underlying causes of non-infectious, immune mediated uveitis is essential for 
appropriate management and to improve overall visual outcomes. However, to date there are no studies 
reviewing the impact of non-infectious uveitis per se, in children from SSA. 
Aim 
Here we aim to describe the disease characteristics and outcomes on immunomodulatory treatment, of 




A retrospective case file review of all children ≤16 years managed for non-infectious uveitis by the 
paediatric ophthalmology and rheumatology units in Cape Town from 1 January 2010 to 31 
December 2017 was conducted. 
Setting and population 
The paediatric rheumatology and ophthalmology tertiary referral units in Cape Town are based at 
Groote Schuur and Red Cross Children’s Hospitals. These hospitals are the main tertiary referral 
centres for the Western Cape as well as other provinces in South Africa, where these paediatric services 
may be minimal or absent.  The Western Cape population numbers  around 6.2 million  and  children 
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<15years constitute 26%. Statistically, the racial profile of the Western Cape region reflects 47.5% 
people of mixed race and differs from the rest of South Africa, where the black African race group is 
more common (46). For the purposes of this study, mixed race refers to everyone not identifying 
themselves as either black African or caucasian. Race is considered here, as associations with 
potentially higher risk and poorer outcomes have been described (28,30). 
Data collection 
1. Children were identified from a systematic review of paediatric rheumatology (PR) and
ophthalmology case files which were correlated with clinic attendance books and confirmed
on the hospital electronic booking system.
2. Data of patients identified with non-infectious uveitis included
o Demographics: age, gender, race (self-reported)
o Clinical presentation
• Date of first presentation, anatomical location of uveitis, visual acuity,
(VA) and complications.
• For uniformity, VA was converted from the recorded Snellen (feet,
metres or decimal) annotation to the log of the minimal angle of
resolution (LogMAR), based on the conversion by Schulze et al (47).
o Disease characteristics and laboratory investigations
o Data of children with JIA additionally included JIA subtype, time to uveitis diagnosis
and whether JIA remission was achieved on treatment.
Disease definitions 
o JIA: as per International League of Associations for Rheumatology criteria (48)
o Idiopathic uveitis: after exclusion of infective and other immune mediated diseases by
clinical assessment and laboratory tests including but not limited to:
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• Toxocara and toxoplasma serology, HIV Elisa or polymerase chain
reaction (PCR), ANA, anti-double stranded DNA, ASOT, AntiDNASe
B, serum angiotensin converting enzyme, Treponema Pallidum
Haemagglutination test and/or Venereal Disease Research Laboratory
test, urine dipstix.
• Ebstein Barr Virus, cytomegalovirus (CMV) and Lyme disease (not
endemic in the Western Cape region of South Africa) serology are not
routinely requested but may be done in individual cases
o Sarcoidosis: Clinical presentation, histology +/- raised serum angiotensin levels
o Behcet’s disease: Clinical diagnosis based on Paediatric BD criteria 2015 (49)
Treatment modalities utilised 
o Standard Initial Treatment includes corticosteroids (topical and/or systemic) and Methotrexate
10–20mg/m2 (maximum dose 20mg orally or 25mg subcutaneously)
o Additional disease modifying anti-rheumatic drug therapy includes azathioprine (1–3mg/kg)
and mycophenolate mofetil (250–500mg/m2 bd)
o Biologics include TNFi Infliximab 6–10mg/kg iv infusion monthly (after loading) and
Adalimumab 20–40mg subcutaneously every second week
Outcome 
o Primary Outcome was considered as clinically inactive disease on treatment.
o Ophthalmology assessments were performed at weekly to 3-monthly intervals depending on
severity of disease. Disease activity at 12 months and at the last clinical visit was evaluated.
Treatment outcome was recorded as at the last clinical visit.
o Anterior chamber disease was assessed utilising the Standard Uveitis Nomenclature (SUN)
criteria (33)
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• Response to treatment defined by the SUN criteria as a two-step
decrease in inflammation or decrease to Grade 0
• Active disease defined by the SUN criteria as  Grade 1 (6–15 cells/slit
lamp field and faint anterior chamber flare)
• Inactive disease defined by the SUN criteria as Grade 0 (<1 cell/slit lamp
field and no anterior chamber flare)
o Remission was defined as   3months of inactive disease on treatment
o Secondary Outcome was considered as improvement in visual acuity
Exclusion criteria 
o All children assessed at the PR service prior to 1 January 2010 and after 31 December 2017
o Children managed for <3 months or were lost to follow up
o Children with active infectious uveitis
Statistical analysis 
Statistical analysis was performed utilising STATA13 software. 
The frequencies of categorical variables were recorded and descriptive statistics employed to 
determine measures of central tendency. Chi squared (or Fisher exact tests if frequencies were <5) and 
t-tests (or Wilcoxon sum rank tests for non-parametric data) for comparisons between groups, were
used as appropriate to evaluate associations with p < 0.05 considered significant. Odds ratios for 
statistically significant variables were calculated to evaluate associated risk. Cox regression model was 
used to assess time to inactive disease and time to uveitis from JIA diagnosis. 
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Results 
Thirty-four children were referred for management of non-infectious uveitis. One with toxocariasis, 2 with 
post streptococcal syndrome and 2 with HIV associated  uveitis were excluded, resulting in 29 children 
meeting inclusion criteria. The overall group had a 0.9:1 female to male ratio, median age at first visit of 74 
months (IQR 49–86 months) and were predominantly of mixed race (72.4%). Bilateral (75.9%), chronic 
anterior uveitis (72.4%) was most frequent. Complications at presentation (55.2%) were predominantly 
cataracts (87.5%) and there was an overall clinical improvement in visual acuity (VA) (Table 2). The 
median time to inactive disease was 7 months (IQR 6-15 months) (Fig. 1). There was no statistical 
difference   (p = 0.28) between JIAU and idiopathic uveitis for overall time to inactive disease (Fig. 2). 19 
(65.5%) children had inactive disease at 12 months after commencement of treatment, including 3 who had 
been started on TNFi subsequent to failure of earlier therapy (Fig. 3). 27 (93.1%) children achieved 
remission, 1 (3.5%) had clinically inactive disease for <3 months and 1 (3.5%) had ongoing active disease 
at the last clinical visit (Table 3).  
Fig 1: Time to inactive disease 
N=28 
Median time to inactive disease:  7 months 
IQR: 6-15 months 
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    Table 2: Disease characteristics 
Diagnosis JIAU Idiopathic Sarcoidosis Behcet’s Disease 










No. of affected eyes 
(CI: 1.6–1.9) 
26 20 4 1 
  Demographics 











Female N (%) 
(CI: 1.3–1.7) 
8 (57.1) 4 (33.3) 2 (100) 0 
Race N (%) 
(CI: 1.1–1.6) 
Mixed 10 (71.4) 9 (75) 1 (50) 1 (100) 
Black African 2 (14.3) 2 (16.7) 1 (50) 0 (0) 
Caucasian 2 (14.3) 1 (8.3) 0 (0) 0 (0) 
Anatomical Location 
(CI: 1.3–2.2) 
Acute Anterior 0 1 (8.3) 1 (50) 0 
Chronic Anterior 14 (100) 6 (50) 0 1 (100) 
Intermediate 0 1 (8.3) 0 0 
Posterior 0 1 (50) 0 
Panuveitis 0 4 (33.4) 0 0 
Laterality 
Unilateral 2 (14.3) 4 (33.3) 0 (0) 1 (100) 
Bilateral 12 (85.7) 8 (66.7) 2 (100) 0 (0) 
Complications 
(CI 1.0 – 1.9) 
No. affected children N (%) 7 (50) 9 (66.6) 0 (0) 0 (0) 
Cataracts 5 (71.4) 9 (100) 0 0 
Posterior synechiae 3 (42.9) 3 (33.3) 0 0 
Band Keratopathy 2 (28.6) 2 (22.2) 0 0 
Raised intra- ocular pressure 3 (42.9) 4 (44.4) 0 0 










VA at last visit 
Median LogMAR (IQR) 0 (0.0–0.2) 0.3 (0.0–0.6) 0 (0–0) 0.1 (-) 
Change in VA: p-value 0.06 0.001 - - 
JIAU: Juvenile Idiopathic Arthritis associated Uveitis, CI: 95% confidence interval, VA: Visual Acuity, LogMAR: Log of minimal 
angle of resolution, where LogMAR 0.0 ~ Snellen 6/ 6, LogMAR 0.5 ~ Snellen 6/19 and LogMAR 1.0 ~ Snellen 6/60 
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Fig 2: Time to inactive disease by diagnosis 
N=28   Behcet’s disease:  3 months 
Sarcoidosis:  median 7 months IQR: 6-8 months 
JIA:  median 6 months IQR: 4-15 months 
Idiopathic: median 10.5 months  IQR: 6-16.5 months 
Fig 3: Inactive disease at 12 months 
N=19 
Standard initial treatment N=16: JIA (9) Idiopathic (4) BD (1) Sarcoidosis (2) 
TNFi N=3:  Idiopathic (2)  JIA (1) 
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(100) 
R 7 (24.1) 1(3.5) 6 (20.7) 2 (7.0) 1 (3.6) 17 (58.6) 
NR 4 (13.8) 2 (7.0) 6 (20.7) 0 0 12 (41.4) 
Azathioprine 8 (72.7) R 1 (12.5) - 0 - - 1 (12.5) 
NR 3 (37.5) -  4 (50) - - 7 (87.5) 
Mycopheno- late 
Mofetil 
3 (27.3) R 1 (33.3) - 0 - - 1 (33.3) 
NR 1 (33.3) - 1 (33.3) - - 2 (66.6) 
Infliximab 6 
(54.5) 
R 1 (16.7) 0 2 (33.3) - - 3 (50) 
NR 1 (16.7) 1 (16.7) 1 (16.7) - - 3 (50) 
Adalimumab 8 
(72.7) 
R 1 (12.5) 2 (25) 4 (50) - - 7 (87.5) 
NR 0 0 1 (12.5) - - 1 (12.5) 
Surgery N (%) 2 (18.2) 1 (33.3) 9 (75) 0 0 12 (41.4) 
Cataract 2 (18.2) 0 6 (50) 0 0 8 (27.5) 
Pars Planar vitrectomy/ lensectomy 0 1 (33.3) 4 (33.3) 0 0 5 (17.2) 
Chelation 0 0 2 (16.7) 0 0 2 (6.8) 
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Responders (R) had inactive disease on treatment. In non-responders (NR), treatment was escalated to one of the additional DMARDs then a TNFi or directly to a TNFi 
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Disease characteristics 
JIAU (48.3%) was the most common diagnosis in a female to male ratio of 1:0.75, at a median 
age of 55 months (IQR 34–86 months), in children predominantly of mixed race (71.4%), with 
chronic anterior uveitis (100%). 
Further analysis in relation to the overall JIA cohort managed during the study period was 
undertaken (Table 5). 229 patients were assessed for JIA of which 12 were excluded according 
to ILAR criteria. 217 were evaluated, with a consequent JIAU clinic prevalence of 6.5%. Three 
children had uveitis for 12, 9 and 4 months prior to the diagnosis of JIA, the majority developed 
uveitis within a year (Figure 4). Comparisons for gender (p = 0.68) and race (p = 0.58) were not 
statistically significant. No children older than 144 months were diagnosed (p = 0.01) with 
uveitis but young age ≤84 months (p = 0.01), oligo-JIA subtype (p = 0.01) and positive ANA 
(p < 0.001) were significant. Univariate analysis showed odds ratios (OR) for possible risk 
factors associated with uveitis as oligo-articular subtype (OR 4.45 CI 1.35–14.7) and positive 
ANA (OR 33.3, CI 6.83–162.09). Older age at diagnosis, 145–192 months (OR1.0 CI 0.6– 1.7) 
appeared to be protective. Reduced VA at presentation was mostly due to cataracts (71.4%).  
Fig 4: Time to uveitis from JIA diagnosis 
 
N=11  
2 children were diagnosed at first screen 
8 children developed uveitis within 1 year of JIA diagnosis, detected at routine screening  
1 child developed uveitis 4 years after initial JIA diagnosis, detected at routine screening 
(3 children had uveitis before JIA diagnosis and were excluded from the model) 
62 
Seven (50%) children had complications with no statistical difference between those diagnosed 
pre-JIA and on screening (p = 0.28). At 12 months from diagnosis, 9 (64.3%) children on 
standard initial treatment and one on TNFi had inactive disease. 57.1% achieved uveitis 
remission on standard initial treatment, 14.3% on additional DMARDs and the refractory 28.6% 
on TNFi treatment. Three were originally commenced on Infliximab and 2 were switched to 
Adalimumab due to lack of efficacy. Of these, one was diagnosed 12 months before arthritis. 
All children in the Adalimumab group achieved remission. Three children had surgery including 
one pars planar vitrectomy/ lensectomy. 
Idiopathic uveitis (41.4%) was the next frequent diagnosis, presenting in males (66.6%), median 
age 76.5 months (IQR 49–156 months) of mixed race (75%). Both eyes were affected in 66.6% with 
chronic anterior uveitis (50%). All children presented with cataracts with median VA LogMAR 
0.95 (0.55–2.45). Four children (33.3%) had inactive disease on standard initial treatment and 2 
(16.7%) on TNFi at 12 months. Remission was achieved in 50% on standard initial treatment, 16.6% 
on Infliximab and 33.3% on Adalimumab as assessed at the last clinical visit. 75% of children 
required surgery. One child did not respond to therapy, was ANA positive and needed evisceration 
of one eye. The overall improvement in VA for the remaining children was statistically significant 
(p = 0.001). 
Sarcoidosis (6.9%) was diagnosed in 2 females. One presented at 49 months, was of mixed race 
and had posterior uveitis. The other, presented at 156 months, was black African and presented 
with acute anterior uveitis. Both had bilateral uveitis and no complications at presentation. Both 
had inactive disease by 12 months, achieved remission on standard initial therapy and had 
preserved vision. 
The 120-month old male of mixed race with BD presented with unilateral chronic anterior 
uveitis, had no complications and responded to standard therapy within 3 months. 
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Table 4: Comparison of JIA only and JIAU 















†p = 0.008 
Age groups 
(months) N (%) 
Odds Ratio 95% 
CI 
0–84 70 (32.3) 60 (29.6) 10 (71.4) †p = 0.01 0.46 CI 0.25–0.83 
85–144 73 (33.6) 69 (33.9) 4 (28.6) p = 0.78 0.71 CI 0.22–2.35 
145–192 60 (27.7) 60 (29.6) 0 †p = 0.01 1.0 CI 0.6–1.7 
Female N (%) 135 (62.2) 127 
(62.5) 
8 (57.1) p = 0.68 0.78 CI 0.26–2.34 
Race N (%) 
Mixed 124 (57.1) 114 
(56.2) 
10 (71.4) p = 0.40 0.72 CI 0.39–1.3 
Black African 37 (17.1) 35 (17.2) 2 (14.3) p = 1.00 1.25 CI 0.27–5.8 
Caucasian 56 (25.8) 54 (26.6) 2 (14.3) p = 0.53 0.46 CI 0.10–2.1 
JIA subtype N (%) 
Oligo-articular 83 (38.3) 73 (35.9) 10 (71.5) †p = 0.01 4.45 CI 1.35–14.7 
Poly articular RF + 18 (8.3) 18 (8.8) 0 p = 0.61 0.08 CI 0.04–0.13 
Poly articular RF – 43 (19.8) 40 (19.7) 3 (21.4) p = 1.00 1.05 CI 0.54–2.04 
Psoriatic 16 (7.4) 15 (7.4) 1 (7.1) p =1.00 0.99 CI 0.59–1.66 
Systemic Onset JIA 17 (7.8) 17 (8.4) 0 p = 0.61 - 
Enthesitis Related 
Arthritis 
38 (17.5) 38 (18.7) 0 p = 0.14 - 
Undifferentiated 2 (0.9) 2 (1) 0 p =1.00 - 








































Non-infectious immune mediated uveitis remains an important cause of ocular morbidity in 
children and despite some advances in the understanding of the underlying pathophysiology, 
sight-threatening complications are still frequently reported (50,51). The dearth of literature 
from Africa and other developing countries, reinforces the perception that these diseases are 
rare or non-existent in children from this setting. Although this assumption has recently been 
challenged (52-54), advocacy for treatment strategies deemed too expensive, regardless of 
proven efficacy elsewhere, is still hindered. 
Here, we have shown that the spectrum and disease characteristics associated with non- 
infectious uveitis are comparable to that of developed countries. However, it is dissimilar to 
reports from North Africa, where BD (23,24) is more common, largely explained by the 
geographic location of this study cohort outside the Mediterranean basin. Importantly, 54.5% 
of our cohort presented with easily identifiable cataracts and posterior synechiae, attesting to 
significant delays in diagnosis. 
Juvenile Idiopathic Arthritis 
Comparison with two studies from developed countries (Table 5), the large multicentre 
Canadian Research in Arthritis in Canadian Children emphasizing Outcomes (ReaCCH-out) 
study cohort and a single centre Atlanta study (27,55), shows similarities in median age of JIA 
presentation, relative frequencies of poly-articular RF negative JIA subtype and ANA 
positivity. However, an older age at JIAU presentation and a lower frequency of oligo-articular 
JIA is seen in our cohort. The prevalence of JIAU here (6.5%) is also lower than reported in 
those studies (8.5% and 18%), as well as other developed country descriptions of up to 20% 
(31). However, our clinic prevalence seems to be in keeping with the few published studies 
from SSA (15, 20, 21, 56).  
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The chronic anterior uveitis, presenting at a younger mean age, significantly in the ≤ 84-month 
age group (p = 0.001), also fits developed country descriptions. Potentially increased risk 
associated with female gender, Caucasian race, oligo-arthritis subtype and positive ANA, need 
further prospective studies to elucidate the role of these variables in our cohort. The majority 
of children with JIAU were ANA positive (78.6%). However, this is in contrast to previous 
studies from South Africa, where children with uveitis had polyarthritis and were ANA 
negative. The differences in JIA subtype and ANA positivity could possibly be ascribed to race. 
The children in our study were predominantly of mixed race, reflecting the racial demographics 
of the Western Cape region of South Africa, compared to the other South African studies, where 
race was reported as black African (15,19). 
A high percentage (21.4%), compared to the 3–7% generally described (57), developed uveitis 
before arthritis was diagnosed. Eleven were detected on screening and half presented with 
complications, 71.4% of which were cataracts. This raises further concerns of diagnostic delays 
in our setting. Notably, treatment was escalated to manage uveitis as arthritis was in remission. 
Idiopathic 
In our study, idiopathic uveitis (36.3%) had a relatively lower frequency, reflecting the small 
number of referred patients. As in other descriptions, refractory disease (58%) with chronic 
anterior and panuveitis, complications and the need for surgery (75%) is noted (58,59). Similar 
severity and poorer outcome were reported in black South African children in a historical study 
by Freedman et al (60), prior to the availability of TNFi. Here, children with refractory disease 
showed significant improvement in disease activity and VA on TNFi treatment. 
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Sarcoidosis 
Sarcoidosis is rare in children and may affect the uveal tract. African American females have 
a ten times increased risk for the development of sarcoidosis but information for African 
children is lacking. In our cohort, both cases were female. The early onset case of mixed race 
was diagnosed on bone marrow biopsy. NOD2 testing was not available at the time. The second 
case, a black African female presented with late onset sarcoidosis diagnosed by systemic 
symptoms, acute anterior uveitis and persistently raised serum angiotensin converting enzyme 
levels. Biopsy results could not be found for this case. Both responded well to systemic 
corticosteroid treatment and methotrexate. TNFi, except etanercept, are used in refractory 
sarcoid uveitis as a second or third line agent. In limited data, most cases show an overall 
improvement in disease activity, although follow up times are relatively short. Escalation to 
TNFi, as has been described in other case series was not needed here (61-64). 
Behcet’s disease 
Adult studies from North Africa, describe a high prevalence of BD (6.25–13%) compared to 
North American and other European populations (0–0.7%) and case series from SSA, highlight 
adults with severe skin and ocular manifestations (24,25,65). Paediatric BD, however, is rarely 
reported from countries outside the geographical area of the former silk route but increased 
prevalence is noted in immigrant children from high prevalence areas compared to the local 
population. The case of clinical BD in our cohort partially fulfilled paediatric BD 2015 criteria, 
as he presented with recurrent uveitis and skin lesions but had less than 3 attacks of oral 
aphthosis per year (49). HLAB51 testing was not done and as far as was known, he was not of 
Mediterranean nor Eastern descent. The chronic anterior uveitis responded well to standard 
initial therapy, in contrast to other case series from North Africa, where posterior uveitis, severe 
ocular complications and poor visual outcome are described in up to 75% (25,66,67). Our 
67 
patient had few recurrences, no complications and near normal vision at the last clinical 
assessment. 
Other immune mediated diseases including Vogt Koyanagi Harada syndrome, Fuch’s 
heterochromic uveitis, tubulointerstitial nephritis associated uveitis, uveitis with SLE and other 
autoinflammatory disorders were not represented in this study. 
Treatment outcome 
Overall, remission on standard initial uveitis treatment (58.6%) endorses its use as first line 
therapy in our resource limited setting. Azathioprine and MMF were used less frequently due 
to gastrointestinal adverse effects and perceived lower efficacy. Neither cyclosporine nor 
intraocular corticosteroid injections were used in our cohort, as low evidence and side effect 
profile in young children were considered to outweigh the benefit (36,45,68,69). TNFi were 
only used in refractory cases due to availability and cost and showed good efficacy. 
Adalimumab was used in conjunction with methotrexate in all our patients and while outcomes 
appeared better than that reported in meta- analyses of previous studies (26,38), this may be 
due to small sample size. Further research into the use of these agents in our setting is needed. 
Table 5: Comparison of JIA and JIAU studies from SSA and developed countries 






Kenya (56) Nigeria (21) Canada (55) Atlanta (27)
Single / Multicentre Single Single Single Single Single Multi Single 
Total N 217 97 85 68 28 1183 287 
JIA subtypes (%) 
Oligo 38.3 39 32.1 23.5 39.3 40 46 
Poly RF– 19.8 30 34.6 38.2 42.8 20 24.4 
Poly RF+ 8.3 9 11.5 17.6 7.1 4 4.5 
ERA 17.5 5 6.4 5.9 0 14 12.9 
Psoriatic 7.4 0 1.3 0 0 6 3.5 
SJIA 7.8 16 14.1 14.7 17.9 6 7.7 
Undifferentiated 0.9 0 0 0 0 10 0.7 




Not all children with immune mediated uveitis may have been referred, thus community 
prevalence is not reflected. Children with JIA are routinely assessed for uveitis screening and 
may be over-represented in this sample. 
Limitations 
This is a retrospective case file review and was dependent on the availability and accuracy of 
the medical records included in the study. 
The SUN working group criteria were applied retrospectively to cases diagnosed prior to 2016 
and required an accurate assessment of clinical notes. 
The small sample size limits inferences that can be made from these results. 
Conclusion 
The spectrum of immune mediated non-infectious uveitis is comparable to that reported in 
developed countries. While current practice detects children with potentially sight-threatening 
disease, delays in diagnosis are a concern. Here, access to tumour necrosis factor inhibitors has 
improved outcomes in refractory cases. Further prospective studies to establish the role of 




ANA Anti-Nuclear Antibody 
ANA HEp2 Anti-Nuclear Antibody Human Epithelial cell indirect immunofluorescence test 
AntiDNAse B Anti-Deoxyribonuclease B 
ASOT Anti-Streptolysin O titres 
ARVs Antiretroviral therapy 
BD Behcet’s Disease 
CMV Cytomegalovirus 
DMARDs Disease Modifying Anti-Rheumatic Drugs 
ERA Enthesitis Related Arthritis 
FHI Fuch’s Heterochromic Iridocyclitis 
HIV Human Immunodeficiency Virus 
HLAB27 Human Leukocyte Antigen B27 
IL Interleukin 
ILAR International League of Associations for Rheumatology 
IQR Interquartile Range 
IRIS Immune Reconstitution Syndrome 
ISG International Study Group 
JIA Juvenile Idiopathic Arthritis 
JIAU Juvenile Idiopathic Arthritis associated Uveitis 
LogMAR Log of the minimal angle of resolution 
MMF Mycophenolate Mofetil 
ReaCCH-out Research in Arthritis in Canadian Children emphasizing Outcomes 
RF Rheumatoid Factor 
SSA sub-Saharan Africa 
SUN Standard Uveitis Nomenclature 
TB Tuberculosis 
TINU Tubulo-Interstitial Nephritis associated Uveitis 
TNFi Tumour Necrosis Factor Inhibitors 
VA Visual Acuity 
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JIA Oligo-arthritis       
JIA Poly-arthritis 
RF- 
      
JIA Poly-arthritis 
RF+ 
      
JIA ERA       
JIA Psoriatic       
JIA 
undifferentiated 
      
JIA systemic       
       
Behcet’s       
Sarcoidosis       
Other       
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Antibody Profile       
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Left eye 
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Posterior Synechiae       
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Other       
       
Treatment       
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Topical 
cycloplegics 
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Other       
       
Surgery       
       
JIA Remission 
(Y/N) 
      
Uveitis Remission 
(Y/N) 
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Signature Removed
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C. Summary of literature search
Search Terms Pubmed SCOPUS Cochrane Library Included 
Epidemiology non-infectious uveitis 
child 
19 1 1 1 
Non-infectious uveitis child Africa 1 1 0 1 
Non-infectious uveitis child treatment 
Africa 
0 0 0 0 
Uveitis rheumatic diseases Africa 4 17 0 3 
Juvenile idiopathic arthritis associated 
uveitis Africa 
2 3 0 3 
Juvenile Idiopathic Arthritis Africa 29 17 0 7 
Biologics juvenile idiopathic arthritis 
uveitis associated uveitis Africa 
0 0 18 0 
Paediatric SLE Africa 14 0 3 
A literature search was performed using the Pubmed (Medline), Scopus (documents) and 
Cochrane Library databases 
18 published articles were reviewed and data relevant to non-infectious immune mediated 
uveitis analysed. Of these, 2 reported the clinical spectrum of uveitis in children and further 
data on uveitis in association with specific diseases were extracted from 16 articles. 
The strength of evidence for non-infectious immune mediated uveitis in African children is 
low and currently relies on few case series/ cohort studies which have other descriptive 
objectives and aims. There is no evidence for the treatment of children in Africa 
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(2015- 2019) UK 
(66) 
Phase II Trial Tocilizumab Results Pending 
Case report 
Di Pasqale Italy 
(2019) (87) 
Single 2 8mg/kg 
every 4 
weeks 
Inactive disease within 2 
weeks and discontinuation 
of prednisone after 1 month 








79% improvement in AC 
cells after 6 weeks, 88% 


















Single 3 Tocilizumab Improvement in macular 
oedema 
Case reports 




Adan et al (2013, 









Improved macular oedema 
Remission with 
Tocilizumab after 
Abatacept, Rituximab and 













Single 8 Rituximab 
1g D1/ D15 
then every 6 
months 
Uveitis control achieved 4-5 
months after infusion, 
except 2 discontinued due 
to ineffective arthritis TX 




Multi centre 10 As above One rituximab cycle follow- 
sup 1 year 7/10 inactivity, 
uveitis recurred in 3 and 












Birolo, Russia 2016 
(76) 




Comparison of ABA as first 
line and after 1 or more 







Multi 21 As above Refractory cases, 7/18 
responded but was not 
sustained 
Case report: 
Kenawy et al India 
2010 (78) 
Single 2 500mg 
weeks 0, 2, 
4 then 
monthly 
Refractory cases - 
Improvement in 
inflammation and macular 
oedema 
Case report 
Elhai 2011 Paris 
(79) 
Single 2 As above Sustained response in 
refractory uveitis 
Zulian, 2010 (80) Single 7 As above Refractory disease failed ≥ 
2 TNFi 
Sustained improvement in 
6/7 cases 
Case report 
Angeles Han, New 
York 2008 (81) 
Single 1 As above Sustained response 
Case reports and case series from predominantly developed countries, where these biologics 
are more readily available, include small numbers of children and show promising results in 
cases refractory to TNFi, for tocilizumab, rituximab and abatacept 
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Language editing services 
Copyright 







Prepare supporting information 




Promoting  your publication 
 
Research article 
Research articles should report on original primary research. 
 
Pediatric Rheumatology strongly encourages that all datasets on which the conclusions of the paper  
rely should be available to readers. We encourage authors to ensure that their datasets are either 
deposited in publicly available repositories (where available and appropriate) or presented in the main 
manuscript or additional supporting files whenever possible. Please see Springer Nature’s information 
on recommended repositories. Where a widely established research community expectation for data 
archiving in public repositories exists, submission to a community-endorsed, public repository is 
mandatory. A list of data where deposition is required, with the appropriate repositories, can be found 
on the Editorial Policies Page. 
 
Preparing your manuscript 
The information below details the section headings that you should include in your manuscript and 
what information should be within each section. 
 
Please note that your manuscript must include a 'Declarations' section including all of the 




The title page should: 
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present a title that includes, if appropriate, the study design e.g.: 
"A versus B in the treatment of C: a randomized controlled trial", "X is a risk factor for 
Y: a case control study", "What is the impact of factor X on subject Y: A systematic 
review" 
or for non-clinical or non-research studies a description of what the article reports 
list the full names and institutional addresses for all authors 
if a collaboration group should be listed as an author, please list the Group name as an 
author. If you would like the names of the individual members of the Group to be 
searchable through their individual PubMed records, please include this information in 
the “Acknowledgements” section in accordance with the instructions below 




The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do not cite 
references in the abstract. Reports of randomized controlled trials should follow the CONSORT 
extension for abstracts. The abstract must include the following separate sections: 
 
Background: the context and purpose of the study 
Methods: how the study was performed and statistical tests used 
Results: the main findings 
Conclusions: brief summary and potential implications 
Trial registration: If your article reports the results of a health care intervention on human 
participants, it must be registered in an appropriate registry and the registration number and 
date of registration should be in stated in this section. If it was not registered prospectively 
(before enrollment of the first participant), you should include the words 'retrospectively 








The Background section should explain the background to the study, its aims, a summary of the 




The methods section should include: 
 
the aim, design and setting of the study 
the characteristics of participants or description of materials 
a clear description of all processes, interventions and comparisons. Generic drug names should 
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generally be used. When proprietary brands are used in research, include the brand names in 
parentheses 




This should include the findings of the study including, if appropriate, results of statistical analysis 




This section should discuss the implications of the findings in context of existing research and 




This should state clearly the main conclusions and provide an explanation of the importance and 
relevance of the study reported. 
 
List of abbreviations 
 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations should be provided. 
 
Declarations 
All manuscripts must contain the following sections under the heading 'Declarations': 
 
Ethics approval and consent to participate 
Consent for publication 





Authors' information (optional) 
 
Please see below for details on the information to be included in these sections. 
 
If any of the sections are not relevant to your manuscript, please include the heading and write 'Not 
applicable' for that section. 
 
Ethics approval and consent to participate 
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Manuscripts reporting studies involving human participants, human data or human tissue must: 
 
include a statement on ethics approval and consent (even where the need for approval was 
waived) 
include the name of the ethics committee that approved the study and the committee’s reference 
number if appropriate 
 
Studies involving animals must include a statement on ethics approval and for experimental studies 
involving client-owned animals, authors must also include a statement on informed consent from the 
client or owner. 
 
See our editorial policies for more information. 
 
If your manuscript does not report on or involve the use of any animal or human data or tissue, please 
state “Not applicable” in this section. 
 
Consent for publication 
 
If your manuscript contains any individual person’s data in any  form  (including  any  individual 
details, images or videos), consent for publication must be obtained from that person, or in the case of 
children, their parent or legal guardian. All presentations of case reports must have consent for 
publication. 
 
You can use your institutional consent form or our consent form if you prefer. You should not send 
the form to us on submission, but we may request to see a copy at any stage (including after 
publication). 
 
See our editorial policies for more information on consent for publication. 
 
If your manuscript does not contain data from any individual person, please state “Not applicable” in 
this section. 
 
Availability of data and materials 
 
All manuscripts must include an ‘Availability of data and materials’ statement. Data availability 
statements should include information on where data supporting the results reported in the article can 
be found including, where applicable, hyperlinks to publicly archived datasets analysed or generated 
during the study. By data we mean the minimal dataset that would be necessary to interpret, replicate 
and build upon the findings reported in the article. We recognise it is not always possible to share 
research data publicly, for instance when individual privacy could be compromised, and in such 
instances data availability should still be stated in the manuscript along with any conditions for   
access. 
 
Data availability statements can take one of the following forms (or a combination of more than one  
if required for multiple datasets): 
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The datasets generated and/or analysed during the current study are available in the [NAME] 
repository, [PERSISTENT WEB LINK TO DATASETS] 
The datasets used and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
All data generated or analysed during this study are included in this published article [and its 
supplementary information files]. 
The datasets generated and/or analysed during the current study are not publicly available due 
[REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author 
on reasonable request. 
Data sharing is not applicable to this article as no datasets were generated or analysed during 
the current study. 
The data that support the findings of this study are available from [third party name] but 
restrictions apply to the availability of these data, which were used under license for the current 
study, and so are not publicly available. Data are however available from the authors upon 
reasonable request and with permission of [third party name]. 
Not applicable. If your manuscript does not contain any data, please state 'Not applicable' in 
this section. 
More examples of template data availability statements, which include examples of openly available 
and restricted access datasets, are available here. 
BioMed Central also requires that authors cite any publicly available data on which the conclusions 
of the paper rely in the manuscript. Data citations should include a persistent identifier (such as a 
DOI) and should ideally be included in the reference list. Citations of datasets, when they appear in 
the reference list, should include the minimum information recommended by DataCite and follow 
journal style. Dataset identifiers including DOIs should be expressed as full URLs. For example: 
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring and 
prediction system (GIDMaPS) data sets. figshare. 2014. 
http://dx.doi.org/10.6084/m9.figshare.853801 
With the corresponding text in the Availability of data and materials statement: 
The datasets generated during and/or analysed during the current study are available in the [NAME] 
repository, [PERSISTENT WEB LINK TO DATASETS].[Reference number]
If you wish to co-submit a data note describing your data to be published in BMC Research Notes, 
you can do so by visiting our submission portal. Data notes support open data and help authors to 
comply with funder policies on data sharing. Co-published data notes will be linked to the research 
article the data support (example). 
For more information please email our Research Data Team. 
Competing interests 
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All financial and non-financial competing interests must be declared in this section. 
 
See our editorial policies for a full explanation of competing interests. If you are unsure whether you 
or any of your co-authors have a competing interest please contact the editorial office. 
 
Please use the authors initials to refer to each authors' competing interests in this section. 
 
If you do not have any competing interests, please state "The authors declare that they have no 




All sources of funding for the research reported should be declared. The role of the funding body in 
the design of the study and collection, analysis, and interpretation of data and in writing the 




The individual contributions of authors to the manuscript should be specified in this section. 
Guidance and criteria for authorship can be found in our editorial policies. 
 
Please use initials to refer to each author's contribution in this section, for example: "FC analyzed and 
interpreted the patient data regarding the hematological disease and the transplant. RH performed the 
histological examination of the kidney, and was a major contributor in writing the manuscript. All 




Please acknowledge anyone who contributed towards the article who does not meet the criteria for 
authorship including anyone who provided professional writing services or materials. 
 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. 
 
See our editorial policies for a full explanation of acknowledgements and authorship criteria.  
If you do not have anyone to acknowledge, please write "Not applicable" in this section. 
Group authorship (for manuscripts involving a collaboration group): if you would like the names of   
the individual members of a collaboration Group to be searchable through their individual PubMed 
records, please ensure that the title of the collaboration Group is included on the title page and in the 
submission system and also include collaborating author names as the last paragraph of the 
“Acknowledgements” section. Please add authors in the format First Name, Middle initial(s)   
(optional), Last Name. You can add institution or country information for each author if you wish, but 
this should be consistent across all authors. 
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Please note that individual names may not be present in the PubMed record at the time a published 




This section is optional. 
 
You  may choose to use this section to include any relevant information about the author(s) that may  
aid the reader's interpretation of the article, and understand the standpoint of the author(s). This may 
include details about the authors' qualifications, current positions they hold at institutions or societies, 
or any other relevant background information. Please refer to authors using their initials. Note this 




Footnotes can be used to give additional information, which may include the citation of a reference 
included in the reference list. They should not consist solely of a reference citation, and they should 
never include the bibliographic details of a reference. They should also not contain any figures or 
tables. 
 
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript 
lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title 
or the authors of the article are not given reference symbols. 
 





Examples of the Vancouver reference style are shown below. 
 
See our editorial policies for author guidance on good citation practice 
 
Web links and URLs: All web links and URLs, including links to the authors' own websites, should 
be given a reference number and included in the reference list rather than within the text of the 
manuscript. They should be provided in full, including both the title of the site and the URL, as well  
as the date the site was accessed, in the following format: The Mouse Tumor Biology Database. 
http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 2013. If an author or group of 
authors can clearly be associated with a web link, such as for weblogs, then they should be included   
in the reference. 
 
Example reference style: 
 
Article within a journal 
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Smith JJ. The world of science. Am J Sci. 1999;36:234-5. 
 
Article within a journal (no page numbers) 
 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. 
Meat consumption and mortality - results from the European Prospective Investigation into Cancer 
and Nutrition. BMC Medicine. 2013;11:63. 
 
Article within a journal by DOI 
 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 
2000; doi:10.1007/s801090000086. 
 
Article within a journal  supplement 
 
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone 
marrow scan. Blood 1979;59 Suppl 1:26-32. 
 
Book chapter, or an article within a book 
 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli 
JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. p. 251-306. 
 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
 
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral 
symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108. 
 
Complete book, authored 
 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 




Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal  





Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. 
Accessed 21 Sept 1998. 
 
Supplementary material/private homepage 
 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 22 Feb 
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ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007. 
 
Dataset with persistent identifier 
 
Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data from sweet and grain 
sorghum (Sorghum bicolor). GigaScience Database. 2011. http://dx.doi.org/10.5524/100012. 
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